<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39557576</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2210-9099</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2024</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Osong public health and research perspectives</Title><ISOAbbreviation>Osong Public Health Res Perspect</ISOAbbreviation></Journal><ArticleTitle>Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.24171/j.phrp.2024.0194</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The aim of this study was to disseminate information about the safety of bivalent coronavirus disease 2019 (COVID-19) mRNA booster vaccines administered to adults in the Republic of Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Two databases were used to assess the safety of COVID-19 booster doses of Pfizer BA.1, Pfizer BA.4/5, Moderna BA.1, and Moderna BA.4/5 vaccines for adults aged 18 years and older. Adverse events (AEs) were analyzed using data reported to the web-based COVID-19 vaccination management system (CVMS) and a self-reported text-message survey.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Between October 11, 2022 and March 30, 2023, the CVMS received reports of 2,369 (93.7%) non-serious AEs from vaccinated adults, along with 158 (6.3%) serious AEs, which included 5 cases of anaphylaxis and 33 deaths. From October 11, 2022 to January 27, 2023, 40,022 people aged 18 and older responded to a survey conducted via text message. The booster doses were associated with fewer local and systemic AEs compared to the original vaccines. After receiving the bivalent vaccine, the most commonly reported AEs were pain at the injection site, headache, fatigue, and myalgia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Overall, bivalent vaccines exhibited fewer AEs compared to the original vaccines. The majority of AEs were non-serious, and serious AEs were rare among adults aged 18 years and older following vaccination with the Pfizer and Moderna bivalent vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seok-Kyoung</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease Control, Bureau of Infectious Disease Policy, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seontae</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease Control and Response, Gyeongnam Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Mijeong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Disease Control Research Planning, Department of Data Science, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Yeseul</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of immunization Policy, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Eun</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease Control and Response, Chungcheong Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yeonkyeong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of immunization Policy, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Juyeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Climate Change and Health Hazard, Department of Health Hazard Response, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahng</LastName><ForeName>Eunok</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Chronic Disease Prevention, Bureau of Chronic Disease Prevention and Control, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Osong Public Health Res Perspect</MedlineTA><NlmUniqueID>101563309</NlmUniqueID><ISSNLinking>2210-9099</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">Bivalent vaccines</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>21</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39557576</ArticleId><ArticleId IdType="doi">10.24171/j.phrp.2024.0194</ArticleId><ArticleId IdType="pii">j.phrp.2024.0194</ArticleId></ArticleIdList></PubmedData></PubmedArticle>